SUPPLEMENTAL MATERIAL

Table S1. PRISMA checklist.

Section and	τ		Reported
Торіс	Item #	Checklist item	on page #
TITLE			
Title	1	Identify the report as a systematic review.	Title page
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	1
INTRODUCTIO	DN		
Rationale	3	Describe the rationale for the review in the context of existing	4-5
		knowledge.	
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the	5
		review addresses.	
METHODS			
Eligibility	5	Specify the inclusion and exclusion criteria for the review and how	6-7
criteria		studies were grouped for the syntheses.	
Information	6	Specify all databases, registers, websites, organisations, reference	6
sources		lists and other sources searched or consulted to identify studies.	
		Specify the date when each source was last searched or consulted.	
Search strategy	7	Present the full search strategies for all databases, registers and	6
		websites, including any filters and limits used.	
Selection	8	Specify the methods used to decide whether a study met the	7
process		inclusion criteria of the review, including how many reviewers	
		screened each record and each report retrieved, whether they	
		worked independently, and if applicable, details of automation	
		tools used in the process.	
Data collection	9	Specify the methods used to collect data from reports, including	7
process		how many reviewers collected data from each report, whether they	

Section and Topic	n and Item # Checklist item					
		worked independently, any processes for obtaining or confirming				
		data from study investigators, and if applicable, details of				
		automation tools used in the process.				
Data items	100		6-9			
Data items	10a	List and define all outcomes for which data were sought. Specify	0-9			
		whether all results that were compatible with each outcome				
		domain in each study were sought (e.g. for all measures, time				
		points, analyses), and if not, the methods used to decide which				
		results to collect.				
	10b	List and define all other variables for which data were sought (e.g.	6-9			
		participant and intervention characteristics, funding sources).				
		Describe any assumptions made about any missing or unclear				
		information.				
Study risk of	11	Specify the methods used to assess risk of bias in the included	10			
bias assessment		studies, including details of the tool(s) used, how many reviewers				
		assessed each study and whether they worked independently, and				
		if applicable, details of automation tools used in the process.				
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio,	9			
		mean difference) used in the synthesis or presentation of results.				
Synthesis	13a	Describe the processes used to decide which studies were eligible	8-9			
methods		for each synthesis (e.g. tabulating the study intervention				
		characteristics and comparing against the planned groups for each				
		synthesis (item #5)).				
	13b	Describe any methods required to prepare the data for presentation	NA			
		or synthesis, such as handling of missing summary statistics, or				
		data conversions.				
	13c	Describe any methods used to tabulate or visually display results	9			

Item #	Checklist item	on page #			
	of individual studies and syntheses.				
13d	Describe any methods used to synthesize results and provide a	9			
	rationale for the choice(s). If meta-analysis was performed,				
	describe the model(s), method(s) to identify the presence and				
	extent of statistical heterogeneity, and software package(s) used.				
13e	Describe any methods used to explore possible causes of	9			
	heterogeneity among study results (e.g. subgroup analysis, meta-				
	regression).				
13f	Describe any sensitivity analyses conducted to assess robustness of	9			
	the synthesized results.				
14	Describe any methods used to assess risk of bias due to missing	10			
	results in a synthesis (arising from reporting biases).				
15	Describe any methods used to assess certainty (or confidence) in	NA			
	the body of evidence for an outcome.				
16a	Describe the results of the search and selection process, from the	10-11			
	number of records identified in the search to the number of studies				
	included in the review, ideally using a flow diagram.				
16b	Cite studies that might appear to meet the inclusion criteria, but	NA			
	which were excluded, and explain why they were excluded.				
17	Cite each included study and present its characteristics.	14-17			
18	Present assessments of risk of bias for each included study.	19-20			
19	For all outcomes, present, for each study: (a) summary statistics	14-19			
	13d 13d 13e 13f 14 14 15 16b 16b	of individual studies and syntheses.13dDescribe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.13eDescribe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta- regression).13fDescribe any sensitivity analyses conducted to assess robustness of the synthesized results.14Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).15Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.16aDescribe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.16bCite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.17Cite each included study and present its characteristics.18Present assessments of risk of bias for each included study.			

Section and		Reported	
Торіс	Item #	Checklist item	on page #
individual		for each group (where appropriate) and (b) an effect estimate and	
studies		its precision (e.g. confidence/credible interval), ideally using	
		structured tables or plots.	
Results of	20a	For each synthesis, briefly summarise the characteristics and risk	19-20
syntheses		of bias among contributing studies.	
	20b	Present results of all statistical syntheses conducted. If meta-	14-19
		analysis was done, present for each the summary estimate and its	
		precision (e.g. confidence/credible interval) and measures of	
		statistical heterogeneity. If comparing groups, describe the	
		direction of the effect.	
	20c	Present results of all investigations of possible causes of	14-19
		heterogeneity among study results.	
	20d	Present results of all sensitivity analyses conducted to assess the	14-15
		robustness of the synthesized results.	
Reporting	21	Present assessments of risk of bias due to missing results (arising	19-21
biases		from reporting biases) for each synthesis assessed.	
Certainty of	22	Present assessments of certainty (or confidence) in the body of	NA
evidence		evidence for each outcome assessed.	
DISCUSSION	<u> </u>		
Discussion	23a	Provide a general interpretation of the results in the context of	21-23
		other evidence.	
	23b	Discuss any limitations of the evidence included in the review.	23
	23c	Discuss any limitations of the review processes used.	23
	23d	Discuss implications of the results for practice, policy, and future	24
		research.	
OTHER INFOR	MATION		

Section and Topic	Item #	Checklist item	Reported on page #
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not	5
		registered.	
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	5
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	5
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	25
Competing interests	26	Declare any competing interests of review authors.	25
Availability of	27	Report which of the following are publicly available and where	NA
data, code and		they can be found: template data collection forms; data extracted	
other materials		from included studies; data used for all analyses; analytic code; any other materials used in the review.	

NA: not applicable

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: http://www.prisma-statement.org/

Table S2. Characteristics of the CIMT measurement.

Study	Definition of CIMT	Area of CIM measurement	Calculation of the overall CIMT	Machine
Bao-Ge <i>et</i> <i>al.</i> ²⁰ 2017	inner surface of the inner membrane - external surface of the tunica media	1 cm proximal to the CCA bifurcation in the left and right CCAs	mean of three separate values	3.5–5 MHz convex probe and a high-resolution B- mode ultrasound scanner
Başyığıt <i>et</i> al. ³⁴ 2012	leading edge of the lumen intimal interface -leading edge of the media adventitia interface of the far wall	NI	mean of right and left values	high-resolution grey-scale Doppler ultrasonography
Diomedi <i>et</i> <i>al.</i> ²⁴ 2004	NI	1.5 cm proximal to the CCA flow divider	mean of the maximum wall thickness for the near and far wall on the left and right side	continuous-wave Doppler and color flow B-mode Doppler ultrasound (Esaote Biomedica, Genova, Italy) with a high-resolution 7.5-MHz linear array-imaging probe
El Hadidy et al. ²⁶ 2009	NI	NI	NI	B mode grey scale ultrasound
Hamed <i>et</i> <i>al.</i> ²¹ 2008	NI	1 cm before carotid bifurcation	mean of the two sides	5-MHz linear transducer of a color duplex flow imaging system (128 XP, Acuson Corp, Mountain View, Calif), modes: real-time B, color, and spectral Doppler

Judaki <i>et</i> al. ³⁵ 2017	NI	NI	average of the measurements of left and right common CIMT	B-mode ultrasonography (Esaote, MylabTM 70 Co., Italy) using a high-resolution, 18-MHz linear array transducer
Karadag <i>et</i> al. ⁴ 2018	distance between the lumen and the intima and the distance between the media and adventitia	1 cm proximal to the carotid bifurcation	average value of the eight measurements on four with 1 mm distant adjacent localizations of the right and left carotid arteries	NI
Köksal <i>et</i> al. ²² 2004	distance between the echoes arising from the intima-media interface and media-adventitia interface	1 cm before the carotid bifurcation at the far wall of the CCA	At least 6 longitudinal and cross-sectional measurements of both CCAs were summarized and a mean CIMT was calculated	linear-array real-time ultrasound equipment with a 7.5-MHz transducer (GE LOGIQ MD 400, Milwaukee, Wisc., USA)
Mayr <i>et</i> <i>al.</i> ²⁵ 2003	lumen-intima interface - leading edge of the media-adventitia interface on the far wall	CCA proximal and distal segments on either side	NI	10-MHz imaging probe and 5-MHz Doppler
Mete <i>et al.</i> ²⁷ 2013	viewable distance between the lumen- intima interface and the mediaadventitia interface	distal 1 cm of CCAs on both sides	CIMT measurements taken from both sides were averaged	grey scale high-resolution color Doppler ultrasound Esaote MyLab 50 (Genoa, Italy) equipped with a 5- 12-MHz linear transducer
Shan <i>et al.</i> ³⁶ 2018	mean of the maximal intimamedia thickness of the near and far walls	1 cm proximal to the flow divider on the distal wall of the CCA	The average of the left and right CIMT values	M-mode examinations, Philips iE33 Ultrasound System, Holland)

Xu et al. ³⁷	leading edge of the media adventitia	1 and 2 cm away from the	mean value between the right and left	Toshiba 790A color Doppler system (Toshiba
2016	interface of the far wall - the leading	bifurcation, and the average of	CCAs	Medical Systems Corporation, Ottawa, Tochigi,
	edge of the lumen intimal interface	the two measurements		Japan) with a 10 MHz transducer
Feng <i>et al.</i> ²³	vertical distance from the edge of the	1.5 cm proximal to the carotid	The average CIMT was obtained from	Doppler ultrasound machine (Siemens G50,
0	E E	-	three independent measurements in the	
2018	first to the second echogenic line	bifurcation	bilateral CCAs	Germany) with a 7.5MHz transducer


CIM: carotid intima-media, CIMT: carotid intima-media thickness, cm: centimeter, CCA: common carotid artery, NI: no information

	N0 of	N ⁰ of <i>H. pylori</i> positivity				H. pylori negativity			
Study	patients	N ⁰ of patients	Sex (female%)	Age (mean±SD)	Overall CIMT (mean±SD)	N ⁰ of patients	Sex (female%)	Age (mean±SD)	Overall CIMT (mean±SD)
Bao-Ge et al. ²⁰ 2017 I.	78	41	12.2	46.37±7.37*	0.84±0.25*	37	8.11	46.72±6.89*	0.76±0.16*
Bao-Ge et al. ²⁰ 2017 II.	82	35	8.57	46.74±6.69*	0.71±0.19*	47	12.77	46.66±6.75*	0.7±0.16*
Başyığıt <i>et al</i> . ³⁴ 2012	61	30	53.33	40.9±10.3	O: 0.71±0.1 L: 0.72±0.14 R: 0.7±0.09	31	51.61	42.3±9.4	O: 0.65±0.06 L: 0.67±0.08 R: 0.64±0.06
Diomedi et al. ²⁴ 2004	124	85	36.47	68.8±9.8	1.13±0.26	39	46.15	66.9±15.8	1.01±0.17
El Hadidy et al. ²⁶ 2009	60	23	82.61	NI	L: 8.08±1.54 R: 7.78±1.41	37	67.57	NI	L: 8.21±1.62 R: 8.16±1.69
Hamed et al. ²¹ 2008 I.	80	68	48.53	47.6±9.1	0.84±0,17	12	66.67	48.2±9.3	0.78±0.1
Hamed <i>et al.</i> ²¹ 2008 II.	60	46	39.13	46.2±9.7	0.62±0.08	14	42.86	50.2±6.5	0.58±0.1
Judaki et al.35 2017	80	40	55	45.64±8.32	0.58±0.13	40	42.5	46.52±5.52	0.48±0.32
Karadag et al. ⁴ 2018	45	24	50	50±8.2	0.78±0.11	21	57.14	52±7.9	0.67 ± 0.08
Köksal et al. ²² 2004 I.	84	63	73.02	46.7±14.7	0.85±0.38	21	66.67	45.1±7.1	0.88±0.3
Köksal <i>et al.</i> ²² 2004 II.	50	30	66.67	45±11	0.56±0.19	20	70	45±10	0.67±0.13
Mayr <i>et al.</i> ²⁵ 2003	421	285	47	56.6†	0.986 ± 0.184	136	49	55.7†	0.991±0.189
Mete <i>et al.</i> ²⁷ 2013	134	103	57.29	49.8±8.7	O: 0.73 (0.34-1.35)‡ L: 0.74 (34-1.6)‡ R: 0.72 (34-1.2)‡	31	61.29	50.2±9.33	O: 0.57 (0.44-0.70)‡ L: 0.55 (0.44-0.67)‡ R: 0.57 (0.4-0.85)‡
Shan <i>et al.</i> ³⁶ 2018	395	186	NI	NI	L: 0.65±0.01 R: 0.65±0.01	209	NI	NI	L: 0.63±0.01 R: 0.61±0.01
Xu et al.37 2016	364	208	46.15	63.2±10.4	1.12±0.18	156	48.1	62.8±11.7	0.93±0.15
Feng et al. ²³ 2018 I.	89	51	19.61	46.1±0.58*	$0.84 \pm 0.009*$	38	21.05	46.79±0.63*	0.76±0.013*
Feng et al. ²³ 2018 II.	91	42	21.43	46.64±0.54*	0.75±0.011*	49	22.45	46.61±0.53*	0.75±0.009*

Table S3. Comparison between *H. pylori* positive and negative participants.


*mean±SE, † mean without SD, ‡ median (min-max), HP: *H. pylori*, SD: standard deviation, SE: standard error, NI: no information, CIMT: carotid intima-media thickness, O: overall, L: left, R: right

Figure S1. Influence diagnostics of the four included studies in the right carotid intimamedia thickness analyses with various methods (Externally Standardized Residuals (rstudent), DFFITS value, Cook's Distance, Covariance Ratio, tau2, Qvalues, Hat & Weight).



1: Başyığıt *et al.* [23] (2012), 2: El Hadidy *et al.* [26] (2009), 3: Mete *et al.* [27] (2013), 4: Shan *et al.* [36] (2018).

Figure S2. Influence diagnostics of the four included studies in the left carotid intimamedia thickness analyses with various methods (Externally Standardized Residuals (rstudent), DFFITS value, Cook's Distance, Covariance Ratio, tau2, Qvalues, Hat & Weight).



1: Başyığıt *et al.* [23] (2012), 2: El Hadidy *et al.* [26] (2009), 3: Mete *et al.* [27] (2013), 4: Shan *et al.* [36] (2018).

Figure S3. Sensitivity analyses of the four included studies in the right and in the left carotid intima-media thickness analyses.






Figure S4. Forest plot of studies comparing right (A) and left (B) carotid intima-media thickness between *Helicobacter pylori* positive and negative individuals without the study published by El Hadidy *et al.*





Black diamonds represent the weighted mean difference between the two groups we compared and horizontal lines show the corresponding 95% confidence intervals (CI). Size of the grey

squares reflect the weight of a particular study. The blue diamond is the overall or summary effect. The outer edges of the diamonds represent the CIs.

Figure S5. A, Meta-regression of age difference. X-axis represents age. The estimate predicts the increase of the effect size, if one was added to the predictor (age, continuous variable) B, Meta-regression of geographical location. X-axis represents the geographical locations, China and Turkey. The estimate predicts the decrease of the effect size, if Turkey was compared to China. C, Meta-regression of detection method. X-axis represents the detection methods, enzyme-linked immunosorbent assay and urea breath test. The estimate predicts the increase of the effect size, if urea breath test was compared to enzyme-linked immunosorbent assay.








In all cases, Y-axis represents the weighted mean differences of overall carotid intima-media thickness in articles reporting these results. Each red dot represents one of these articles.

Figure S6. Forest plot of studies comparing the prevalence of diabetes mellitus (A) and hypertension (B) between *Helicobacter pylori* positive and negative individuals.



Black diamonds represent the odds ratios and horizontal lines show the corresponding 95% confidence intervals (CI). Size of the grey squares reflect the weight of a particular study. The

blue diamond is the overall or summary effect. The outer edges of the diamonds represent the CIs.

Figure S7. Forest plot of studies comparing the mean age between *Helicobacter pylori* positive and negative individuals.




Figure S8. Forest plot of studies comparing total cholesterol levels between *Helicobacter pylori* positive and negative individuals.




Figure S9. Forest plot of studies comparing triglyceride levels between *Helicobacter pylori* positive and negative individuals.





Figure S10. Forest plot of studies comparing low-density lipoprotein levels between *Helicobacter pylori* positive and negative individuals.



Black diamonds represent the weighted mean difference between the two groups we compared and horizontal lines show the corresponding 95% confidence intervals. Size of the grey squares reflect the weight of a particular study. The blue diamond is the overall or summary effect. The outer edges of the diamonds represent the CIs.

Figure S11. Forest plot of studies comparing high-density lipoprotein levels between *Helicobacter pylori* positive and negative individuals.




Figure S12. Forest plot of studies comparing overall carotid intima-media thickness between *Helicobacter pylori* positive and negative Chinese individuals.




Figure S13. Forest plot of studies comparing overall carotid intima-media thickness between *Helicobacter pylori* positive and negative Turkish individuals.




Figure S14. Forest plot of studies comparing overall carotid intima-media thickness between *Helicobacter pylori* positive and negative individuals if the pathogen was detected by urea breath test.




Figure S15. Forest plot of studies comparing overall carotid intima-media thickness between *Helicobacter pylori* positive and negative individuals if the pathogen was detected by enzyme-linked immunosorbent assay.





Figure S16. Bar charts for all domains separately included in risk of bias assessment of overall (A), right (B) and left (C) carotid intima-media thickness.


Overall CIMT



Some concerns ■ High risk ■ NA


В

Right CIMT






Left CIMT



Α

Green represents low risk of bias, yellow represents moderate and red represents high risk of bias. Grey represents non-applicability of the subdomain for the study. X-axis represents the percentage of each risk and the domains are represented on Y-axis.

Figure S17. Funnel plot of studies comparing overall carotid intima-media thickness between *Helicobacter pylori* positive and negative individuals.



X-axis represents the weighted mean difference between the two groups we compared. Y-axis represents the standard error of weighted mean difference. The vertical is for overall effect. The dashed lines represent the 95% confidence intervals. Each spot represents an included study of the specific analysis.